Warfarin and bevacizumab suppress tumor progression in pancreatic ductal adenocarcinoma by targeting EGFR-PI3K-Akt signaling: inhibition of proliferation/migration and apoptosis induction
The warfarin-bevacizumab combination synergistically impaired PDAC progression via multi-tiered EGFR-PI3K-Akt suppression and mitochondrial apoptosis activation, providing a rationale for clinical translation against oncogenic pathway plasticity.
Authors
- Jingting Wang (ORCID: https://orcid.org/0000-0002-1028-177X)
- Limei Yang
- Jianjie Ju (ORCID: https://orcid.org/0009-0004-7906-7773)
- Jingjing Chen
Institutions
- Fujian Medical University (CN)
- Fujian Provincial Hospital (CN)
Publication Details
- Journal
- Translational Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.21037/tcr-2025-1190
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05